课题基金 / 基金详情

Study of antigenic variation in Malaria for malaria vaccine.

Study of antigenic variation in Malaria for malaria vaccine.
疟疾疫苗的疟原虫抗原变异研究。
批准号:
05044168
负责人:
HORII Toshihiro
金额:
$6.72万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for international Scientific Research
财政年份:
1993
资助国家:
日本
项目状态:
已结题
起止时间:
1993 至 1995

项目摘要

项目成果

HORII Toshihiro的其他基金

相似基金

相关文献

中文摘要
翻译
血清(丝氨酸重复抗原,113 kDa)是恶性疟原虫的一种寄生空泡抗原。一种血清蛋白,可与流行区人血浆中的免疫球蛋白发生交叉反应,并在体外与抑制寄生虫生长的单抗交叉反应。为了开发疟疾疫苗,我们通过构建密码子用法改变的合成基因,建立了重组血清蛋白在大肠杆菌中的表达系统。我们构建了含47 kDa N-末端结构域、23 kDa中央结构域和C-末端结构域(Sugiyama et al.,in Press)的合成基因,用编码血清17-382个氨基酸残基(N-末端结构域)的重组产物SE47‘蛋白免疫小鼠和大鼠,诱导产生针对培养寄生虫的生长抑制抗血清。用无佐剂的十二烷基硫酸钠变性的SE47‘蛋白免疫动物,获得的抗血清抑制率最高。这一观察结果表明,SE47‘蛋白的一级结构对应于生长抑制抗体的诱导。由于蛋白质倾向于聚集在水溶液中,分子内或分子间的疏水相互作用可能掩盖了关键区域对宿主免疫系统的有效呈现。我们推测弗氏佐剂可能与SE47‘蛋白具有疏水相互作用(Sugiyama等人,同上)。SERA基因在分离株中被认为是很保守的,但我们发现诱导保护性抗体的N末端区域比基因的其他部分更容易发生氨基酸变化。针对N-末端区域开发的保护性免疫可能会加快该区域的进化速度(Morimatsu,Horii等人,正在准备中)。
英文摘要
SERA (serine repeat antigen, 113 kDa) is a parasitophorous vacuole antigen of Plasmodium falciparum. SERA protein that cross-reacts with IgG in human plasma from an endemic area and with a monoclonal antibody inhibitory against the parasite growth in vitro. For developing malaria vaccine, we have developed the expression system of recombinant SERA proteins in E.coli by constructing the synthetic genes with the altered codon usage. We have constructed synthetic genes covering three parts of SERA including N-terminal domain with 47 kDa, central domain with 23 kDa and C-terminal domain with (Sugiyama et al., in press).When mice or rats were immunized with SE47' protein that is one of the recombinant products encoding 17-382 amino acid residues of SERA (N-terminal domain), the growth inhibitory anti-sera against the cultural parasites were induced. The most inhibitory anti-sera was obtained when the animals were immunized with SDS-denatured SE47' protein without any adjuvants. This observation suggests that the primary structure of SE47' protein corresponds to the induction of growth inhibitory antibodies. Since the protein tends to aggregate in the aqueous solution, the hydrophobic interaction of intra or inter molecules might mask the effective presentation of the critical region to the host immune system. We suppose that the Freund's adjuvant may have a hydrophobic interaction with SE47' protein (Sugiyama et al., ibid).SERA gene is thought to be well conserved among the isolated strains, however, we found that the amino acid changes are more often occurred in the N-terminal region that induce protective antibody than the other parts of gene. The protective immunity developed against the N-terminal region may accelerate the evolution speed in the region (Morimatsu, Horii et al., in preparation).
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
T.Sugiyama, K.Suzue, M.Okamoto, J.Inselburg, K.Tai and T.Horii: "Production of recombinant SERA proteins of Plasmodium falciparum in E.coli by using synthetic genes." Vaccine. (in press).
T.Sugiyama、K.Suzue、M.Okamoto、J.Inselburg、K.Tai 和 T.Horii:“利用合成基因在大肠杆菌中生产恶性疟原虫的重组 SERA 蛋白。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
T.Sugiyama,K.Suzue,M.Okamoto,J.Inselburg,K.Tai and T.Horii: "Recombinant SERA proteins of Plasmodium falciparum induce growth inhibitory anti-sera against asexual stage of malaria parasite" Moiecular and Biochemical Parasitology. (Submitted)
T.Sugiyama、K.Suzue、M.Okamoto、J.Inselburg、K.Tai 和 T.Horii:“恶性疟原虫的重组 SERA 蛋白诱导针对疟疾寄生虫无性阶段的生长抑制抗血清”分子和生化寄生虫学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
How P.vivax parasite maintains multiple infection in areas of low intensity malaria?
  • 批准号:
    20590422
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $3.0万
  • 财政年份:
    2008
  • 负责人:
    HORII Toshihiro
  • 依托单位:
Clinical trial of SE36 malaria vaccine in the endemic area
  • 批准号:
    17256003
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
  • 资助金额:
    $26.21万
  • 财政年份:
    2005
  • 负责人:
    HORII Toshihiro
  • 依托单位:
Basic study for the recombinant SERA malaria vaccine development
  • 批准号:
    13226058
  • 项目类别:
    Grant-in-Aid for Scientific Research on Priority Areas
  • 资助金额:
    $35.84万
  • 财政年份:
    2001
  • 负责人:
    HORII Toshihiro
  • 依托单位:
MALARIA VACCINE DEVELOPMENT BASED ON THE RECOMBINANT SERA
  • 批准号:
    13357002
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
  • 资助金额:
    $26.54万
  • 财政年份:
    2001
  • 负责人:
    HORII Toshihiro
  • 依托单位:
海外基金